Multicenter Assessment of the Pancreas in Type 1 Diabetes
MAP-T1D
3 other identifiers
observational
250
2 countries
5
Brief Summary
The overall goal of this research is to develop and validate standard operating procedures (SOP) to assess the human pancreas in individuals with type 1 diabetes (T1D) and other forms of diabetes using advanced, quantitative magnetic resonance imaging (MRI) approaches.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2014
Longer than P75 for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 19, 2014
CompletedFirst Submitted
Initial submission to the registry
June 18, 2018
CompletedFirst Posted
Study publicly available on registry
July 12, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2050
October 31, 2025
October 1, 2025
14.8 years
June 18, 2018
October 9, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Pancreas Volume Index
Size of the pancreas determined by longitudinal MRI, normalized to subject weight
up to 10 years
Secondary Outcomes (1)
MRI of pancreas - Apparent Diffusion Coefficient
up to 10 years
Study Arms (4)
Individuals with stage 3 T1D
Individuals with overt stage 3 type 1 diabetes
Healthy control
Individuals without type 1 diabetes
Autoantibody positive
Individuals with early stage type 1 diabetes (stage 1, stage 2) who possess two or more type 1 diabetes-related autoantibodies
Monogenic diabetes
Individuals with monogenic diabetes
Interventions
subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
Eligibility Criteria
Individuals with diabetes for this study may be referred by any pediatric or adult endocrinologists. Healthy controls are recruited via a passive recruitment process. A small subset of controls will travel to multiple study centers to have an MRI. In this study, the MRI scan will be used for research purposes only. However, if we see something that is not normal, the participant will be told and asked to consult his or her doctor.
You may qualify if:
- Subjects at least 8 years of age
- Subjects with T1D must be imaged within 100 days of their date of diagnosis
- Subjects must be able to read and provide assent/informed written consent
You may not qualify if:
- Subjects with pancreatitis, cystic fibrosis, pancreatic adenocarcinoma, or neuroendocrine tumors
- Subjects who have any type of bioimplant activated by mechanical, electronic, or magnetic means because such devices may be displaced or malfunction
- Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced
- Subjects who are pregnant or breast-feeding. Urine pregnancy test will be performed on women of child bearing potential who are not practicing appropriate contraception measures or menstruating.
- Subjects who exhibit significant anxiety and/or claustrophobia
- Subjects incapable of giving assent/informed written consent
- For controls: subjects who have first degree relatives with T1D
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Vanderbilt University Medical Centerlead
- University of Texas at Austincollaborator
- University of Chicagocollaborator
- University of Colorado, Denvercollaborator
- St Vincent's Institute of Medical Researchcollaborator
- Juvenile Diabetes Research Foundationcollaborator
Study Sites (5)
University of Colorado, Barbara Davis Center
Aurora, Colorado, 80045, United States
University of Chicago, Kovler Diabetes Center
Chicago, Illinois, 60637, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
University of Texas at Austin, Dell Medical School
Austin, Texas, 78712, United States
St. Vincent's Institute of Medical Research
Melbourne, Victoria, Australia
Related Publications (3)
Virostko J, Williams J, Hilmes M, Bowman C, Wright JJ, Du L, Kang H, Russell WE, Powers AC, Moore DJ. Pancreas Volume Declines During the First Year After Diagnosis of Type 1 Diabetes and Exhibits Altered Diffusion at Disease Onset. Diabetes Care. 2019 Feb;42(2):248-257. doi: 10.2337/dc18-1507. Epub 2018 Dec 14.
PMID: 30552135RESULTWilliams JM, Hilmes MA, Archer B, Dulaney A, Du L, Kang H, Russell WE, Powers AC, Moore DJ, Virostko J. Repeatability and Reproducibility of Pancreas Volume Measurements Using MRI. Sci Rep. 2020 Mar 16;10(1):4767. doi: 10.1038/s41598-020-61759-9.
PMID: 32179809RESULTWright JJ, Dulaney A, Williams JM, Hilmes MA, Du L, Kang H, Powers AC, Moore DJ, Virostko J. Longitudinal MRI Shows Progressive Decline in Pancreas Size and Altered Pancreas Shape in Type 1 Diabetes. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2699-2707. doi: 10.1210/clinem/dgad150.
PMID: 36938587DERIVED
Biospecimen
Whole blood; mouth saliva swab; urine
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alvin C. Powers, MD
Vanderbilt University Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Medicine
Study Record Dates
First Submitted
June 18, 2018
First Posted
July 12, 2018
Study Start
February 19, 2014
Primary Completion (Estimated)
December 1, 2028
Study Completion (Estimated)
December 1, 2050
Last Updated
October 31, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will not share